title: Effect of darunavir on lipid profile in HIV-infected patients.
abstract: Highly active antiretroviral therapy regimens, consisting of a ritonavir-boosted protease inhibitor (PI) and 2 nucleoside reverse transcriptase inhibitors, are established first-line regimens for HIV-infected patients. However, a common adverse effect in patients receiving PIs is dyslipidemia, characterized by increases in plasma levels of triglycerides, low-density lipoprotein cholesterol, and total cholesterol (TC). These lipid changes, as well as other well-described risk factors, may predispose patients to the development of cardiovascular disease, an important comorbidity, especially as the lifespan of HIV-infected patients has increased dramatically in recent years. Among PIs, ritonavir-boosted atazanavir (ATV/r) and, more recently, ritonavir-boosted darunavir (DRV/r) have demonstrated potent antiviral efficacy with more favorable lipid profiles than other PIs. This review provides an overview of the lipid effects of DRV/r. Studies with DRV/r in healthy volunteers and in both treatment-naïve and -experienced patients have demonstrated that changes in tri-glycerides and TC are comparable to those seen with ATV/r.
authors.affiliation: University of Alabama, Birmingham, AL 35294, USA. toverton@im.wustl.edu
authors.forename: Edgar Turner
authors.initials: ET
authors.lastname: Overton
authors.forename: Eduardo
authors.initials: E
authors.lastname: Arathoon
authors.forename: Ezio
authors.initials: E
authors.lastname: Baraldi
authors.forename: Frank
authors.initials: F
authors.lastname: Tomaka
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000069454:Darunavir; D050171:Dyslipidemias / Q000139:chemically induced*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008055:Lipids / Q000097:blood*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D008055:Lipids; D013449:Sulfonamides; D000069454:Darunavir